DVA vs. LH, DGX, CHE, RCM, CRVL, AMED, AMN, MD, CCRN, and FMS
Should you be buying DaVita stock or one of its competitors? The main competitors of DaVita include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Chemed (CHE), R1 RCM (RCM), CorVel (CRVL), Amedisys (AMED), AMN Healthcare Services (AMN), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Fresenius Medical Care (FMS).
Laboratory Co. of America (NYSE:LH) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk.
Laboratory Co. of America presently has a consensus price target of $243.14, suggesting a potential upside of 23.93%. DaVita has a consensus price target of $144.67, suggesting a potential upside of 0.69%. Given DaVita's stronger consensus rating and higher probable upside, equities research analysts clearly believe Laboratory Co. of America is more favorable than DaVita.
Laboratory Co. of America has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
95.9% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.9% of Laboratory Co. of America shares are owned by insiders. Comparatively, 2.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
DaVita has lower revenue, but higher earnings than Laboratory Co. of America. DaVita is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
Laboratory Co. of America received 108 more outperform votes than DaVita when rated by MarketBeat users. Likewise, 64.14% of users gave Laboratory Co. of America an outperform vote while only 61.70% of users gave DaVita an outperform vote.
DaVita has a net margin of 6.61% compared to DaVita's net margin of 3.52%. Laboratory Co. of America's return on equity of 68.52% beat DaVita's return on equity.
In the previous week, Laboratory Co. of America and Laboratory Co. of America both had 7 articles in the media. DaVita's average media sentiment score of 1.20 beat Laboratory Co. of America's score of 1.20 indicating that Laboratory Co. of America is being referred to more favorably in the media.
Summary
Laboratory Co. of America beats DaVita on 11 of the 17 factors compared between the two stocks.
Get DaVita News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
